$7.01 Billion in Sales Expected for AstraZeneca PLC (NASDAQ:AZN) This Quarter

Share on StockTwits

Wall Street brokerages expect AstraZeneca PLC (NASDAQ:AZN) to post sales of $7.01 billion for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for AstraZeneca’s earnings. The lowest sales estimate is $6.78 billion and the highest is $7.24 billion. AstraZeneca posted sales of $6.66 billion during the same quarter last year, which indicates a positive year-over-year growth rate of 5.3%. The firm is expected to issue its next earnings results on Friday, February 12th.

According to Zacks, analysts expect that AstraZeneca will report full year sales of $26.22 billion for the current financial year, with estimates ranging from $25.99 billion to $26.45 billion. For the next year, analysts expect that the business will report sales of $30.68 billion, with estimates ranging from $30.45 billion to $30.92 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that follow AstraZeneca.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings data on Thursday, November 5th. The company reported $0.47 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.49 by ($0.02). AstraZeneca had a net margin of 9.65% and a return on equity of 37.23%. The firm had revenue of $6.58 billion during the quarter, compared to analyst estimates of $6.54 billion.

Several equities analysts have issued reports on AZN shares. Piper Sandler decreased their price target on shares of AstraZeneca from $179.00 to $175.00 and set an “overweight” rating for the company in a research report on Sunday, December 13th. AlphaValue upgraded AstraZeneca to a “reduce” rating in a report on Wednesday, December 30th. UBS Group restated a “positive” rating on shares of AstraZeneca in a report on Monday, December 14th. Morgan Stanley raised AstraZeneca from an “equal weight” rating to an “overweight” rating in a research note on Monday, December 7th. Finally, Berenberg Bank initiated coverage on AstraZeneca in a research note on Tuesday, September 29th. They issued a “buy” rating for the company. Two research analysts have rated the stock with a sell rating, three have given a hold rating and ten have issued a buy rating to the company’s stock. AstraZeneca has a consensus rating of “Buy” and an average price target of $83.80.

Several hedge funds have recently made changes to their positions in the company. Johnson Financial Group Inc. acquired a new stake in shares of AstraZeneca in the 3rd quarter valued at about $26,000. Clear Harbor Asset Management LLC acquired a new stake in AstraZeneca in the third quarter valued at approximately $27,000. Simon Quick Advisors LLC acquired a new stake in AstraZeneca in the third quarter valued at approximately $30,000. HM Payson & Co. acquired a new stake in AstraZeneca in the third quarter valued at approximately $30,000. Finally, Adams Wealth Management acquired a new stake in AstraZeneca in the 3rd quarter valued at $30,000. 15.57% of the stock is owned by institutional investors.

Shares of AstraZeneca stock traded up $0.59 on Wednesday, hitting $50.88. The stock had a trading volume of 11,442,400 shares, compared to its average volume of 12,387,961. The company has a debt-to-equity ratio of 1.34, a quick ratio of 0.76 and a current ratio of 0.96. AstraZeneca has a twelve month low of $36.15 and a twelve month high of $64.94. The stock has a 50 day moving average of $49.87 and a 200 day moving average of $52.75. The firm has a market capitalization of $133.54 billion, a P/E ratio of 53.00, a PEG ratio of 1.40 and a beta of 0.55.

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR/Komboglyze, Onglyza, Qtern, Symlin, Xigduo/Xigduo XR for metabolic diseases.

Read More: Fundamental Analysis

Get a free copy of the Zacks research report on AstraZeneca (AZN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AstraZeneca (NASDAQ:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.